Cantor Fitzgerald Trims Marinus Pharmaceuticals (NASDAQ:MRNS) Target Price to $4.00
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) had its price objective lowered by analysts at Cantor Fitzgerald from $13.00 to $4.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. A number of other brokerages also recently commented on MRNS. LADENBURG THALM/SH SH downgraded […]
25 Oct 16:39 · The Markets Daily